ID   5F11
AC   CVCL_WT46
DR   ABCD; ABCD_AD047
DR   Wikidata; Q93308285
RX   PubMed=12881320;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was developed by Medarex into a therapeutic mAB known as Iratumumab (MDX-060) to be used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30.
CC   Miscellaneous: As the immunized splenic B-cells are from HuMAb mice the produced mAB is of human origin.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 05-07-19; Last updated: 21-03-23; Version: 5
//
RX   PubMed=12881320; DOI=10.1182/blood-2003-02-0515;
RA   Borchmann P., Treml J.F., Hansen H., Gottstein C., Schnell R.,
RA   Staak O., Zhang H.-F., Davis T., Keler T., Diehl V., Graziano R.F.,
RA   Engert A.;
RT   "The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity
RT   against malignant lymphoma.";
RL   Blood 102:3737-3742(2003).
//